Other languages 89bio, Inc.

Equities

ETNB

US2825591033

Market Closed - Nasdaq Other stock markets 21:00:00 02/05/2024 BST			5-day change	1st Jan Change
8.86 ^USD	+1.26%		+7.39%	-20.68%

04-17	89bio, Inc. Appoints Martin Babler to Its Board of Directors	CI
04-03	89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

89bio, Inc. Appoints Martin Babler to Its Board of Directors	04-17
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	04-03
Sector Update: Health Care Stocks Gain Wednesday Afternoon	03-27
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status	03-27
89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis and Compensated Cirrhosis	03-27
89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis, Formerly Known as Nonalcoholic Steatohepatitis	03-12
Top Premarket Gainers	03-04
89bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-29
89bio Insider Sold Shares Worth $560,000, According to a Recent SEC Filing	01-03
89bio Prices Upsized $150 Million Offering of Common Shares, Pre-Funded Warrants	12-07
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	12-07
89bio Launches $125 Million Offering of Common Shares, Pre-Funded Warrants	12-07
Sector Update: Health Care Stocks Rise Late Afternoon	12-04
Sector Update: Health Care Stocks Rise Monday Afternoon	12-04
89bio Share Rise on Advance Into Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis	12-04
89bio, Inc. Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis	12-04
89bio Sees 'Positive' Long-Term Results From Phase 2b Study of Pegozafermin to Treat Nonalcoholic Steatohepatitis	11-27
89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis	11-27
89bio Says Liver Disease Phase 2 Trial of Pegozafermin Showed 'Clinically Meaningful' Improvements in Biomarkers	11-13
89Bio Announces Additional Data from the Enliven Phase 2B Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis	11-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages 89bio, Inc.

Equities

ETNB

US2825591033

Other languages

Filters